"So triple negative means that they are ER Negative, PR Negative, HER-2 Negative and those patients cannot be driven by those receptors. And there is actually a pretty good literature that at least some of those patients will likely be driven by AR. So hope we've done by signing that studies and to reach the population that we believe is more likely to be AR responsive. So that's one way that we could be also have generated a preclinical data in our collaboration with the University of Colorado showing that XTANDI also inhibits estrogen BD in the breast cancer growth. Now that is a pathway that is separate from the AR, because estrogen works through a separate receptor called the ER.
We know that XTANDI does not hit the ER, but as you know, the way receptors always work is that a - buying to receptor and that activates a number of downstream events and we believe that given the fact that we have shown to inhibit single preclinical studies.
We believe that which has the possibility that XTANDI is working at some other target more difficult in that pathway, in estrogen pathway. So that really two possible ways that we could be working in breast cancer, one is to the AR pathway and hopefully see you at in the triple negative - but we also believe there is a possible a possibility that XTANDI could work against estrogen - and so I think those will be the two macros which we would expect to see some results."
http://www.earningsimpact.com/Transcript/82077/MDVN/JMP-Securities-2013-Healthcare-Conference
We know that XTANDI does not hit the ER, but as you know, the way receptors always work is that a - buying to receptor and that activates a number of downstream events and we believe that given the fact that we have shown to inhibit single preclinical studies.
We believe that which has the possibility that XTANDI is working at some other target more difficult in that pathway, in estrogen pathway. So that really two possible ways that we could be working in breast cancer, one is to the AR pathway and hopefully see you at in the triple negative - but we also believe there is a possible a possibility that XTANDI could work against estrogen - and so I think those will be the two macros which we would expect to see some results."
http://www.earningsimpact.com/Transcript/82077/MDVN/JMP-Securities-2013-Healthcare-Conference